Asston Pharmaceuticals Limited

As of March 31, 2026, Asston Pharmaceuticals Limited carries a market capitalization of 621.40M, placing it among publicly traded companies globally. Its enterprise value stands at 659.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Asston Pharmaceuticals Limited has 8.51M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Asston Pharmaceuticals Limited maintains a current ratio of 4.51, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Asston Pharmaceuticals Limited recorded 13.42M in income tax expense.

As of the close on October 22, 2026, Asston Pharmaceuticals Limited's stock has gained approximately 41.97% over the past 52 weeks. The 50-day moving average sits at 99.88, while the 200-day moving average is 84.96.

As of March 31, 2026, Asston Pharmaceuticals Limited holds 12.91M in cash and equivalents against 51.08M in total debt, resulting in a net debt position of 38.17M. Total book value stands at 388.62M, with working capital of 315.87M providing operational flexibility.